The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection-Reference-Cited by-同舟云学术

The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Published:2022-11-11 Issue:7 Volume:76 Page:1315-1317
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Barda Noam¹²³⁴^ORCID,Canetti Michal⁴⁵⁶^ORCID,Gilboa Mayan⁴⁵⁶,Asraf Keren⁶⁷,Indenboim Victoria⁶⁸,Weiss-Ottolenghi Yael⁴⁵⁶,Amit Sharon⁶⁹,Zubli Daniel⁴⁵,Doolman Ram⁶⁸,Mendelson Ella⁶⁷,Freedman Laurence S¹⁰,Kreiss Yitshak⁶¹¹,Lustig Yaniv⁶⁸,Regev-Yochay Gili⁴⁵⁶

Affiliation:

1. ARC Innovation Center, Sheba Medical Center , Tel Hashomer, Ramat Gan , Israel

2. Software and Information Systems Engineering, Ben-Gurion University of the Negev , Be'er Sheva , Israel

3. Epidemiology, Biostatistics and Community Health Sciences, Ben-Gurion University of the Negev , Be'er Sheva , Israel

4. Sheba Pandemic Preparedness Research Institute, Sheba Medical Center , Ramat-Gan , Israel

5. Infection Prevention and Control Unit, Sheba Medical Center , Tel Hashomer, Ramat Gan , Israel

6. Sackler School of Medicine, Tel-Aviv University , Tel-Aviv , Israel

7. Dworman Automated-Mega Laboratory, Sheba Medical Center , Ramat-Gan , Israel

8. Central Virology Laboratory, Public Health Services, Ministry of Health , Ramat-Gan , Israel

9. Clinical Microbiology, Sheba Medical Center , Ramat-Gan , Israel

10. Biostatistics and Biomathematics Unit, Gertner Institute of Epidemiology and Health Policy Research , Ramat-Gan , Israel

11. General Management, Sheba Medical Center , Tel Hashomer, Ramat Gan , Israel

Abstract

Abstract The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.

Funder

Sheba Medical Center

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac886/47659033/ciac886.pdf

Reference15 articles.

1. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

2. Decreased infectivity following BNT162b2 vaccination: a prospective cohort study in Israel;Regev-Yochay;Lancet Reg Health Eur,2021

3. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study;Barda;Lancet,2021

4. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar;Chemaitelly;N Engl J Med,2021

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers;Vaccine;2024-12

2. Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan;Vaccine;2024-08

3. Knowledge of the Serological Response to the Third BNT162b2 Vaccination May Influence Compliance of Healthcare Workers to Booster Dose;Antibodies;2024-08-01

4. Anti‐Spike IgG antibodies as correlates of protection against SARS‐CoV‐2 infection in the pre‐Omicron and Omicron era;Journal of Medical Virology;2024-08

5. Antibody levels and the risk of SARS-CoV-2 infection during the Omicron surge;GHM Open;2024-07-26